• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Qatar·Healthcare·QGMD.QA
Share

Qatari German Company for Medical Devices (Q.P.S.C.) Stocks

QAR 1.27Last Updated 15.10.2026

Issuer Rating

2/7
Performance

Poor

Risk

Moderate

Recommendation

Sell

Market Cap

QAR 41.25M

QAR 1.27
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Qatari German Company for Medical Devices (Q.P.S.C.), operating from its headquarters in Doha, Qatar, was established in 2000. This company primarily focuses on the manufacturing and sale of single-use, disposable syringes across the Middle East. Its diverse product line features the Q JectUltra insulin syringe for diabetes care, the Q Flow series for infusion therapy, the Q Need disposable hypodermic needle, the Q Ject syringe for dispensing curative medications, and the Q Safe, an innovative syringe designed to prevent reuse. Additionally, the firm engages in the trade of various medical equipment, tools, and general supplies.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

17.10.2026 21:12

DeepSeek unveils updated AI model claimed to be faster than its predecessor

17.10.2026 16:01

Small caps last week: Russell 2000 correction, Bumble sale, Crocs celeb partnerships

17.10.2026 13:01

The Weak Link in the AI Revolution: Big Pharma Comes to the Rescue of Investors; Burry Believes in Mortgages

17.10.2026 03:47

‘All of this is going to pass’: Nvidia CEO is confident AI rally will continue

17.10.2026 03:37

"Musk Magic" Is Back: CFRA Analyst Raises Tesla's Price Target Due to the Flying Car

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026